Havens Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Havens Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$2.39M	Buy	+21,000	New	+$1.74M	6.07%	6

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Havens Advisors's HZNP Position: Q4 2022 in Review

Havens Advisors opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022: 21,000 shares worth $2.39M. The stake represents 6.07% of the portfolio and ranks #6 among its holdings.

615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Havens Advisors held 21,000 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $2.39M as of Q4 2022.
Horizon Therapeutics Public Limited Company Ordinary Shares was a new Havens Advisors position in Q4 2022.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 6.07% of Havens Advisors's portfolio in Q4 2022, its #6 holding.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Havens Advisors's 13F filing for Q4 2022, filed 25 Jan 2023.